ArticleVirology journal2017
Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women.
Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Article
- Clinical epidemiology and associations between HPV infection and vaginal infections in Jinan, China: a cross-sectional analysis.Frontiers in cellular and infection microbiology · 2026Article
- Nationwide epidemiology of HPV E6/E7 mRNA in China: genotype distribution in 11,118 women.Frontiers in public health · 2026Article
- Prevalence and genotype distribution of HPV infection among women in Chengdu from 2019 to 2024: a retrospective single-center study.Infectious agents and cancer · 2025Article
- Role of NTRK Fusion Genes in the Tumor Immune Microenvironment of HPV (+/-) Cervical Cancer.Journal of medical virology · 2025Review
- Characterization of human papillomavirus genotypes infections in patients with cervical lesions and cervical cancer in Urumqi, Xinjiang from 2016 to 2023.Virology journal · 2025Article
- A Comprehensive Evaluation of the HPV Neutralizing Antibodies in Guangzhou, China: A Comparative Study on Various HPV Vaccines.Vaccines · 2024Article
- Epidemiological study of human papillomavirus infection in 105,679 women in Wuhan, China.BMC infectious diseases · 2024Article
- Prevalence and Genotype Distribution of Human Papillomavirus Infection Among Women in Wuhan, China: A Retrospective Study.Infection and drug resistance · 2024Article
- Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022.Virology journal · 2023Article
- The Burden of HPV-Related Hospitalizations: Analysis of Hospital Discharge Records from the Years 2015-2021 from a Southern Italian Region.Pathogens (Basel, Switzerland) · 2023Article
- Impact of Preventive Strategies on HPV-Related Diseases: Ten-Year Data from the Italian Hospital Admission Registry.Cancers · 2023Article
- Cervical HPV infection in Yueyang, China: a cross-sectional study of 125,604 women from 2019 to 2022.Frontiers in public health · 2023Article
- Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China.Virology journal · 2022Article
- Cervical cancer screening in high-altitude areas in China: A large cross-section study of 25,173 women in northern Tibet.Frontiers in oncology · 2022Article
- Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016-2020.Virology journal · 2021Article
- The genomic distribution map of human papillomavirus in Western China.Epidemiology and infection · 2021Article
- Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province, China: a three years surveys prior to mass HPV vaccination.Virology journal · 2020Article
- HPV infection screening using surface plasmon resonance in women from Kunming (Southwest China).Bosnian journal of basic medical sciences · 2020Article
- Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China.Infectious agents and cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge-size data on type-specific HPV prevalence in Southwest China are required to estimate the cervical cancer burden in the country and to prepare for HPV-based cervical screening program and further HPV vaccination of China. This HPV study is a pooled analysis of data from five years in Chongqing of China, which is cross-sectional in design using data collecting.
resultsThe positivity of HPV was 26.2% (10542/40311), single type was 25.7% (10360/40311), multiple type was 8.2% (3306/40311), high-risk HPV was 30.9% (12490/40311), and low-risk HPV was 2.9%(1169/40311). The most common genotypes were HPV16,52,58 and 18. HPV-positive women (n = 10542) were triaged by cytology, colposcopy or histological diagnosis. Among HPV-positive women, 43.8% had normal, 22.5% had ASCUS, 0.2% had LSIL, 12.6% had HSIL and 6.0% had ICC. The most common HPV genotypes were HPV16, 58 and 18 in ASCUS, HPV16, 18 and 58 in LSIL, HPV16, 58 and 33 in HSIL, and HPV16, 58 and 18 in ICC. The prevalence of Group 1/2A HPV types increased with increasing CIN grade and accounted for 96.05% of the CIN 3+ lesions, while HPV16 accounted for 71.1%. HPV-positive women steadily increased with age, peaking at 31-40 years.
conclusionThe type-specific prevalence rate of HPV 16 and HPV 18 were a little lower than the mean of international meta-analyses. Single HPV genotype infection was predominantly detected in different groups of cervical lesions in Chongqing, and HPV16, 52, 58 were the priority HPV types. The HPV genotyping study was found to be valuable for planning further preventive program for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.